NASDAQ:ICCC

ImmuCell Stock Forecast, Price & News

$10.12

-0.12 (-1.17 %)

(As of 07/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$10.00

▼

$10.28

50-Day Range

$9.00

▼

$10.39

52-Week Range

$4.98

▼

$13.20

Volume1,505 shs

Average Volume24,782 shs

Market Capitalization$78.33 million

P/E RatioN/A

Dividend YieldN/A

Beta0.9

30 days | 90 days | 365 days | Advanced Chart

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
July 9, 2021 | markets.businessinsider.com

BRIEF-ImmuCell Says Expects To Reduce Backlog Of Orders During Q3
July 8, 2021 | msn.com

ImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021
July 7, 2021 | finance.yahoo.com

Should I Buy Vertex Energy Inc (VTNR)? - Yahoo Finance Australia
June 21, 2021 | finance.yahoo.com

Here's Why ImmuCell Corporation's (NASDAQ:ICCC) CEO May Deserve A Raise - Yahoo Finance
June 10, 2021 | finance.yahoo.com

Here's Why ImmuCell Corporation's (NASDAQ:ICCC) CEO May Deserve A Raise
June 10, 2021 | finance.yahoo.com

The animal pharmaceuticals market was valued USD45.23 billion in 2020 and is likely to grow with a steady CAGR of 7.05% in the forecast period to reach USD68.45 billion by 2026 - GlobeNewswire
June 3, 2021 | globenewswire.com

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders - GlobeNewswire
May 19, 2021 | globenewswire.com

ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2021 - GlobeNewswire
May 14, 2021 | globenewswire.com

ImmuCell Corporation (ICCC) CEO Michael Brigham on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
May 14, 2021 | seekingalpha.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICCC
Previous Symbol
CUSIPN/A
CIK811641
Webwww.immucell.com
Phone207-878-2770
Employees52
Year FoundedN/A

Sales & Book Value

Annual Sales$15.34 million
Price / Sales5.11
Cash Flow$0.20 per share
Price / Cash Flow51.72
Book Value$3.92 per share
Price / Book2.58

Profitability

EPS (Most Recent Fiscal Year)($0.14)
Net Income$-1,020,000.00
Net Margins-9.22%
Return on Equity-4.77%
Return on Assets-3.34%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares7,740,000
Market Cap$78.33 million
Next Earnings Date8/11/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.58 out of 5 stars

Medical Sector

1493rd out of 2,218 stocks

Diagnostic Substances Industry

28th out of 38 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for ImmuCell.

2.9 Community Rank

Outperform Votes
ImmuCell has received 120 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ImmuCell has received 87 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ImmuCell has received 57.97% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote “Outperform” if you believe ICCC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ImmuCell does not currently pay a dividend.
Dividend Growth
ImmuCell does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ImmuCell insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 14.90% of the stock of ImmuCell is held by insiders.
Percentage Held by Institutions
Only 9.66% of the stock of ImmuCell is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of ImmuCell is -56.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ImmuCell is -56.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ImmuCell has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

Is ImmuCell a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmuCell in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ImmuCell stock.
View analyst ratings for ImmuCell or view top-rated stocks.

What stocks does MarketBeat like better than ImmuCell?

Wall Street analysts have given ImmuCell a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ImmuCell wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ImmuCell?

ImmuCell saw a decrease in short interest in July. As of July 15th, there was short interest totaling 7,800 shares, a decrease of 25.7% from the June 30th total of 10,500 shares. Based on an average trading volume of 16,600 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.1% of the company's shares are short sold.
View ImmuCell's Short Interest.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for ImmuCell.

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) posted its earnings results on Thursday, May, 13th. The biotechnology company reported ($0.06) EPS for the quarter, missing the Zacks' consensus estimate of $0.05 by $0.11. The biotechnology company earned $4.11 million during the quarter. ImmuCell had a negative net margin of 9.22% and a negative trailing twelve-month return on equity of 4.77%.
View ImmuCell's earnings history.

How has ImmuCell's stock been impacted by Coronavirus?

ImmuCell's stock was trading at $4.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ICCC stock has increased by 135.3% and is now trading at $10.12.
View which stocks have been most impacted by COVID-19.

What guidance has ImmuCell issued on next quarter's earnings?

ImmuCell updated its second quarter 2021 earnings guidance on Wednesday, July, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $4.50 million-$4.50 million, compared to the consensus revenue estimate of $3.26 million.

Who are ImmuCell's key executives?

ImmuCell's management team includes the following people:

Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 60, Pay $354.27k)
Dr. Joseph H. Crabb Ph.D., VP & Chief Scientific Officer (Age 66, Pay $54.98k)
Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 44, Pay $314.8k)
Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 65, Pay $255.65k)
Elizabeth S. Toothaker, Director of Fin. & Admin.
Mr. A. Gustavo Scaffa, Sr. Director of Quality
John W. Zinckgraf, Director of Product Devel.

Who are some of ImmuCell's key competitors?

Some companies that are related to ImmuCell include Quotient (QTNT), MyMD Pharmaceuticals (MYMD), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), Navidea Biopharmaceuticals (NAVB), Achieve Life Sciences (ACHV), Biomerica (BMRA), ARCA biopharma (ABIO), Trinity Biotech (TRIB), Global WholeHealth Partners (GWHP), StageZero Life Sciences (SZLSF), StageZero Life Sciences (GNWSF), StageZero Life Sciences (GNWSD), Fuse Science (DROP) and BG Medicine (BGMD).
View all of ICCC's competitors.

What other stocks do shareholders of ImmuCell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ImmuCell investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Biocept (BIOC), Amarin (AMRN), CorMedix (CRMD), CRISPR Therapeutics (CRSP), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Pfizer (PFE).

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $10.12.

How much money does ImmuCell make?

ImmuCell has a market capitalization of $78.33 million and generates $15.34 million in revenue each year. The biotechnology company earns $-1,020,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

How many employees does ImmuCell have?

ImmuCell employs 52 workers across the globe.

What is ImmuCell's official website?

The official website for ImmuCell is www.immucell.com.

Where are ImmuCell's headquarters?

ImmuCell is headquartered at 56 EVERGREEN DR, PORTLAND ME, 04103.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]

This page was last updated on 7/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here